THE WYSONG e-HEALTH LETTER
U.S. FDA SAYS ABBOTT HIV DRUG ADS MISLEADING: Two Abbott Laboratories Inc. ads for HIV-fighting drug Kaletra exaggerated benefits and left out information about life-threatening safety risks, per U.S. Food and Drug Administration (FDA). The FDA ordered the company to stop circulating the advertisements immediately, which ran in magazines aimed at people with HIV. Further, the FDA stated that both ads implied Kaletra could help patients with AIDS, stay healthy for five years. The ads were misleading because Kaletra was approved based on studies lasting 48 and 72 weeks. "FDA is not aware of substantial evidence or substantial clinical experience to support claims of survival, good health, undetectable HIV (blood) levels and disease control for five years," the agency said. The ads also failed to mention potential side effects, which can include life-threatening interactions with other drugs, the FDA said.
SWEET MISERY: Aspartame is found in more than 5,000 food and drink products. One woman who was using aspartame-sweetened products and fighting multiple sclerosis stopped using aspartame and her symptoms went away miraculously. Aspartame is a slow neurotoxin which is unfit for human consumption. In addition, the amount of propaganda and "dirty tricks," that big businesses use to get aspartame on the US market, and the domino effect it has had on other countries is a study in all that is wrong with capitalism without conscience. (http://www.newswithviews.com/NWVexclusive/exclusive27.htm)
SPLENDA: Splenda, the common tabletop sweetener that was introduced in 1988, is a chlorocarbon known to cause an array of health problems such as organ, genetic, and reproductive damage. This may explain why Splenda has been linked to 40 % shrinkage of the thymus gland, a seat of immune function. Further, Splenda causes swelling of the liver, calcification of the kidneys, fertility and gastrointestinal problems. The makers of Splenda state that the chlorine atoms in Splenda are altered and therefore safe, yet it is known that any animal that consumes chlorine is at an increased risk of cancer.
OLESTRA & THE TRUTH BEHIND "LIGHT" CHIPS: The Center for Science & Public Interest (CPSI) has been following the side effects associated with "light" potato chips - most widely seen as Frito-Lay's previous WOW! Brand. These new 'light" chips are merely the old olestra (a diarrhea inducing synthesized fat) fried brand marketed under a fake "healthy" option. The CPSI is trying to deter consumers from eating Lay's Light, Ruffles Light, Doritos Light and Tostitos Light chips - all using olestra. Thus far the FDA has received more than 20,000 individual reports of olestra-induced reactions, including diarrhea, cramps and bleeding. Further, making matters worse, the FDA no longer requires olestra-based chips manufacturers to carry the previously apt warning label: "This product contains Olestra. Olestra may cause abdominal cramps and loose stools. Olestra inhibits the absorption of some vitamins and other nutrients. Vitamins A, D, E and K have been added." (http://www.cspinet.org/new/200410251.html)
HIGH FLUORIDE LEVELS IN INSTANT TEA: The popular instant tea beverage may be a source of harmful levels of Fluoride. The data indicates that some regular strength preparations contain as much as 6.5 ppm of fluoride. The EPA's maximum level is set at 4 ppm maximum level for drinking water and 2.4 ppm in bottled water and beverages. The tea plant is known to accumulate fluoride from the soil and water. (Whyte, et al. (2005). Skeletal fluorosis and instant tea. Am J Med. Jan; 118(1): 78-82.)
LACTOFERRIN COULD HELP IN OSTEOPOROSIS FIGHT: Taking supplements of lactoferrin or a drink enriched with this milk protein may help prevent osteoporosis in those at risk. Lactoferrin not only inhibits bone breakdown but also boosts bone growth four times faster than normal when injected directly into bone, a latest New Zealand study reported. (Cornish et al. (2004). Endocrinology; V 145, no 9, pp 4366-4374.)
STOMACH STAPLING KILLS: Many health professionals have expressed concerns about women having gastric bypass surgery during their childbearing years. If a woman becomes pregnant too soon after surgery she is putting herself and her baby at risk of death. The first death of this type occurred two years ago to an obese woman and her unborn child. Women make up the majority of the 110,000 people who have had gastric bypass surgery, mostly during their childbearing years. Since the surgery lessens the number of nutrients available to a fetus and can lead to serious infections, many physicians prescribe contraceptives for two years after the surgery to avoid pregnancy until a woman's weight is stabilized. Pregnancies tend to be more common after surgery because fertility rises with major weight loss. (Pratt et al., (2004) Case 25-2004 - A 49-Year-Old Woman with Severe Obesity, Diabetes, and Hypertension. N. Engl. J Med. V. 351 (7): 696-705.)Current statistics on stomach stapling indicates that:
DOCUMENTS EXPOSE PHARMACEUTICAL SALES TACTICS: What Merck & Co. calls good salesmanship - emphasizing the positive in selling the painkiller Vioxx, is disinformation designed to deflect safety concerns. The public got an extraordinary glimpse Thursday into the world of drug marketing, as lawmakers released confidential Merck documents that detail how a sales army of 3,000 aggressively pushed the multibillion-dollar drug before it was withdrawn from the market last fall due to heart attack risks. Sales representatives were offered $2,000 bonuses for meeting sales goals, and worked in campaigns with code-names such as "Project Offense" to try to boost sales even as regulators were about to increase warnings on the drug's label. Some of the instructions given to the sales people:
The Wysong e-Health Letter is an educational newsletter. Opinions expressed are meant to be taken for their argumentative/intellectual interest value, and not interpreted as specific medical or legal direction for individual conditions or situations. The e-Health Letter does not represent all-inclusive knowledge, nor can it affirm or deny facts or data gathered from cited references. Before initiating any health action or changing existing therapies, individuals should read the references cited in the e-Health Letter or request them from Wysong Corporation (eHealthLetter@wysong.net), and seek and evaluate several alternative, competent viewpoints. The reader (not the Wysong e-Health Letter) must assume all responsibilities from the application of educational and often controversial information presented in the e-Health Letter.
© Copyright 2005, Wysong Corporation This newsletter is for educational purposes. Material may be copied and transmitted provided the source (Dr. Wysong's e-Health Letter, http://www.wysong.net ) is clearly credited, context is clearly described, its use is not for profit in any way, and mention is made of the availability of the free Wysong e-Health Letter. For any other use, written permission is required.